Wall Street Icon: “You must get on the right side of this thing”

I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.

This market shakeup is going to be much more intense.

John Hamer Biography and Net Worth

Director of AbCellera Biologics

John is a Managing General Partner at DCVC Bio, a San Francisco venture capital fund focused on building the next generation of life science companies. John has held positions as Managing Partner and Founder of Monsanto Growth Ventures, Managing Director and Entrepreneur-in-Residence at Burrill & Co. Prior to venture capital, John held senior management positions at Paradigm Genetics Inc./Icoria, (NASDAQ::PDGM) including CSO, CEO and EVP for Business Development. John has a PhD in Microbiology from the University of California, Davis and was Professor of Biological Sciences at Purdue University where he was a Packard Fellow and NSF Presidential Faculty Fellow.

How do I contact John Hamer?: The corporate mailing address for Dr. Hamer and other AbCellera Biologics executives is , , . AbCellera Biologics can also be reached via phone at 604-559-9005 and via email at [email protected]. Learn More on John Hamer's contact information.
Has John Hamer been buying or selling shares of AbCellera Biologics?: John Hamer has not been actively trading shares of AbCellera Biologics within the last three months. Most recently, John Hamer sold 162,649 shares of the business's stock in a transaction on Tuesday, August 31st. The shares were sold at an average price of $16.95, for a transaction totalling $2,756,900.55. Learn More on John Hamer's trading history.
Who are AbCellera Biologics' active insiders?: AbCellera Biologics' insider roster includes Andrew Booth (CFO), John Hamer (Director), Carl Hansen (CEO), Michael Hayden (Director), Veronique Lecault (COO), Andrew Lo (Director), and John Montalbano (Director). Learn More on AbCellera Biologics' active insiders.

John Hamer Insider Trading History at AbCellera Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/31/2021	Sell	162,649	$16.95	$2,756,900.55

John Hamer Buying and Selling Activity at AbCellera Biologics

AbCellera Biologics Company Overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Today's Range

Now: $2.85

$2.68

$2.88

50 Day Range

MA: $2.82

$2.52

$3.15

2 Week Range

Now: $2.85

$2.34

$6.05

Volume

2,074,423 shs

Average Volume

1,770,256 shs

Market Capitalization

$841.79 million

P/E Ratio

N/A

Dividend Yield